Agios Pharmaceuticals, Inc.
https://www.agios.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agios Pharmaceuticals, Inc.
Agios Shows Pyrukynd Can Reduce Transfusions In Thalassemia
Having already posted Phase III success in non-transfusion dependent patients, Agios’s Pyrukynd now has shown the ability to reduce transfusions in alpha and beta thalassemia patients.
Agios Extends Cash Runway With $905m Royalty Pharma Deal
Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.
EHA Preview: Agios Takes Spotlight In Thalassemia
The company expects to have data from transfusion-dependent and non-transfusion dependent patients this year, with a potential expanded US approval in 2025 for Pyrukynd.
Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline
Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice